Celldex Therapeutics, INC 10-Q quarterly reports

Celldex Therapeutics reports Q1 2026 results, highlighting significant progress in barzolvolimab development for urticaria and other conditions, alongside increased R&D spending.

Celldex Therapeutics reported increased net losses in Q3 2025 due to higher R&D expenses for barzolvolimab, while maintaining sufficient liquidity through 2027 and advancing multiple clinical programs.

Celldex Therapeutics reports increased net loss driven by higher R&D expenses for its lead drug barzolvolimab, while maintaining strong liquidity and advancing multiple clinical programs.

Celldex Therapeutics reported a net loss of $53.8 million for Q1 2025, driven by increased R&D spending as it advances its barzolvolimab program.

Celldex Therapeutics reports a net loss of $110.8 million for the first nine months of 2024, while highlighting progress in its clinical programs, particularly with barzolvolimab.

Celldex Therapeutics reports a net loss of $68.7 million for the first half of 2024, while advancing its clinical programs, particularly barzolvolimab, across multiple indications.

Celldex Therapeutics reports a significant increase in cash and marketable securities to $823.8 million, driven by successful public offerings, while advancing its clinical programs.